Last year Receptos pulled off one of the most successful biotech IPOs in a red-hot market for new offerings, largely on the promise of a midstage study underway for its oral multiple sclerosis drug. And this morning investors spurred a 35% spike in its share price as investigators spelled out promising data from that Phase II trial.

…read more

Source: Receptos shares spike as oral drug reduces brain lesions in PhII MS trial


0 No comments